In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to ...

French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company ...

MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected] MaaT Pharma – Media Relations Pauline RICHAUD Senior PR ...

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning the biotech to seek approval of the microbiome therapy in Europe in mid ...

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

EXCLUSIVE: Strig Artist Management is bolstering its team, bringing on Christina Montojo as Manager and promoting Maat Bates from Assistant to Coordinator. Montojo moves to Strig Artist Management ...

Kepher-Maat, who is based in Los Angeles, will report to Scott Shooman, the company’s executive vice president and head of a film group encompassing three brands: IFC Films, RLJE Films and Shudder.

Kepher-Maat also gives New York-based IFC an additional presence in LA, he noted. Last year across the labels were 30 Shudder movies, 12 IFC Films and eight RLJE, not all released theatrically.

Mike ter Maat, the Libertarian Party’s 2024 vice presidential nominee, has switched to the Republican Party, aligning with the Republican Liberty Caucus.

The MAAT houses three distinct spaces: MAAT Central, previously a thermal power station from 1908 and now home to The Electricity Factory, a permanent exhibition; MAAT Gallery, ...

MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival ...